BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 26333933)

  • 1. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva.
    Lees-Shepard JB; Yamamoto M; Biswas AA; Stoessel SJ; Nicholas SE; Cogswell CA; Devarakonda PM; Schneider MJ; Cummins SM; Legendre NP; Yamamoto S; Kaartinen V; Hunter JW; Goldhamer DJ
    Nat Commun; 2018 Feb; 9(1):471. PubMed ID: 29396429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
    Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
    J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
    Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
    J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.
    Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P
    Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
    Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
    J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
    Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
    Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV-Mediated Targeting of the Activin A-ACVR1
    Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.
    Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC
    J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
    Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.
    Haupt J; Deichsel A; Stange K; Ast C; Bocciardi R; Ravazzolo R; Di Rocco M; Ferrari P; Landi A; Kaplan FS; Shore EM; Reissner C; Seemann P
    Hum Mol Genet; 2014 Oct; 23(20):5364-77. PubMed ID: 24852373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
    Wang H; Shore EM; Pignolo RJ; Kaplan FS
    Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable signaling activity by FOP ACVR1 mutations.
    Haupt J; Xu M; Shore EM
    Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish.
    Allen RS; Tajer B; Shore EM; Mullins MC
    Elife; 2020 Sep; 9():. PubMed ID: 32897189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.